

2021 CF Registry Data Highlights

CFRI participants

1315 participants in CFRI in 2021
Registered, alive & not lost to follow-up.

97.6% of individuals had data from a clinic visit recorded in 2021 (n= 1293)

796 adults 18+

519 children <18


27 new-borns diagnosed with CF*

Female 42.2%

Male 57.8%

+45 newly consented individuals in CFRI

*Via the National Newborn Bloodspot Screening Programme



Age distribution

Median survival age

13.4% of the CFRI population is over 40

39.9 2011-2015

51.8 2017-2021

an increase from **4.4%** of the CFRI population in 2010

Median age

22.4

Half the CF population is under 22.4

Half the CF population is over 22.4

Key stats*

Adults (18+)

Children

*shown as a % of 1293 individuals with data from a clinical visit in 2021

Median best ppFEV ₁	77.4%	96.0%
Complications (top 3 most prevalent)	Reflux 55.1% Sinus 40.3% Diabetes 30.6%	Reflux 21.6% Sinus 5.6% Liver disease 4.1%
Microbiology (% chronic status)	P. aeruginosa 21.0% S. aureus 18.6%	P. aeruginosa 2.5% S. aureus 30.5%
Median best BMI (*Z-Score)	24.0	0.45 ^a

CFTR Modulator therapy*

*shown as a % of 1293 individuals with data from a clinical visit in 2021




76.7% % eligible & taking CFTRm **18.1%** % eligible & not taking CFTRm **5.2%** % ineligible

N.B. Patients may be eligible for more than 1 CFTRm. Patients may have switched modulators over the course of the year.

Outpatient visits

6,283 outpatient encounters recorded in 2021



Hospitalisations

257 individuals required hospitalisation

425 hospitalisations recorded in total for the 257 individuals

55% hospitalisations were for treating a pulmonary exacerbation